目的:对西药联合桂枝加厚朴杏子汤和玉屏风散对稳定期慢阻肺的疗效与安全性进行系统评价。方法:检索万方数据库、中国知网数据库、维普中文科技期刊数据库、PubMed、Web of Science、Embase、Cochrane Library、中国生物医学文献等数据...目的:对西药联合桂枝加厚朴杏子汤和玉屏风散对稳定期慢阻肺的疗效与安全性进行系统评价。方法:检索万方数据库、中国知网数据库、维普中文科技期刊数据库、PubMed、Web of Science、Embase、Cochrane Library、中国生物医学文献等数据库,检索时限为建库至2023年9月,以西药联合桂枝加厚朴杏子汤和玉屏风散对稳定期慢阻肺的随机对照试验为研究对象,对照组实施常规西医治疗,研究组在对照组治疗的基础上加用桂枝加厚朴杏子汤和玉屏风散。对纳入文献进行质量评价和资料提取,采用RevMan 5.3软件进行数据分析。结果:共纳入9项研究,共788例患者。Meta分析结果显示:研究组临床总有效率优于对照组[RR = 1.23, 95%CI (1.15, 1.32), P Objective: The efficacy and safety of Western medicine combined with Guizhi and Houpu Xingzi decoction and Yupingfeng Powder in the treatment of stable COPD were systematically evaluated. Methods: Search Wanfang database, China Knowledge Network database, VIP Chinese sci-tech journal database, PubMed, Web of Science, Embase, Cochrane Library, Chinese biomedical literature database, etc. were searched, with retrieval time from database establishment to September 2023. The randomized controlled trial of Western medicine combined with Guizhi and Houpu Xingzi decoction and Yupingfeng Powder on stable COPD was used as the object of study. The control group was treated with routine Western medicine. The study group was treated with Guizhi and Houpu Xingzi decoction and Yupingfeng powder on the basis of treatment in the control group. The quality of the included literature was evaluated and the data were extracted, and the data were analyzed by RevMan 5.3 software. Results: A total of 788 patients were included in 9 studies. The results of Meta-analysis showed that the total clinical effective rate of the study group was better than that of the control group [RR = 1.23, 95%CI (1.15, 1.32), P < 0.00001], the improvement of FEV1 in the study group was better than that of the control group [MD = 0.33, 95%CI (0.28, 0.37), P < 0.00001], the improvement of FEV1/FVC in the study group was better than that of the control group [MD = 8.89, 95%CI (6.89, 10.90), P < 0.00001], and the incidence of adverse reactions in the study group was lower than that in the control group [MD = 0.22, 95%CI (0.12, 0.41), P < 0.00001]. Conclusion: Western medicine combined with Guizhi and Houpu Xingzi decoction and Yupingfeng Powder in the treatment of stable COPD can significantly improve patients’ total clinical effective rate, increase FEV1 and FEV1/FVC, and reduce the incidence of adverse reactions.展开更多
文摘目的:对西药联合桂枝加厚朴杏子汤和玉屏风散对稳定期慢阻肺的疗效与安全性进行系统评价。方法:检索万方数据库、中国知网数据库、维普中文科技期刊数据库、PubMed、Web of Science、Embase、Cochrane Library、中国生物医学文献等数据库,检索时限为建库至2023年9月,以西药联合桂枝加厚朴杏子汤和玉屏风散对稳定期慢阻肺的随机对照试验为研究对象,对照组实施常规西医治疗,研究组在对照组治疗的基础上加用桂枝加厚朴杏子汤和玉屏风散。对纳入文献进行质量评价和资料提取,采用RevMan 5.3软件进行数据分析。结果:共纳入9项研究,共788例患者。Meta分析结果显示:研究组临床总有效率优于对照组[RR = 1.23, 95%CI (1.15, 1.32), P Objective: The efficacy and safety of Western medicine combined with Guizhi and Houpu Xingzi decoction and Yupingfeng Powder in the treatment of stable COPD were systematically evaluated. Methods: Search Wanfang database, China Knowledge Network database, VIP Chinese sci-tech journal database, PubMed, Web of Science, Embase, Cochrane Library, Chinese biomedical literature database, etc. were searched, with retrieval time from database establishment to September 2023. The randomized controlled trial of Western medicine combined with Guizhi and Houpu Xingzi decoction and Yupingfeng Powder on stable COPD was used as the object of study. The control group was treated with routine Western medicine. The study group was treated with Guizhi and Houpu Xingzi decoction and Yupingfeng powder on the basis of treatment in the control group. The quality of the included literature was evaluated and the data were extracted, and the data were analyzed by RevMan 5.3 software. Results: A total of 788 patients were included in 9 studies. The results of Meta-analysis showed that the total clinical effective rate of the study group was better than that of the control group [RR = 1.23, 95%CI (1.15, 1.32), P < 0.00001], the improvement of FEV1 in the study group was better than that of the control group [MD = 0.33, 95%CI (0.28, 0.37), P < 0.00001], the improvement of FEV1/FVC in the study group was better than that of the control group [MD = 8.89, 95%CI (6.89, 10.90), P < 0.00001], and the incidence of adverse reactions in the study group was lower than that in the control group [MD = 0.22, 95%CI (0.12, 0.41), P < 0.00001]. Conclusion: Western medicine combined with Guizhi and Houpu Xingzi decoction and Yupingfeng Powder in the treatment of stable COPD can significantly improve patients’ total clinical effective rate, increase FEV1 and FEV1/FVC, and reduce the incidence of adverse reactions.
